New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 17, 2014
16:45 EDTVRX, AGNPershing Square looks to obtain consents for special meeting
Pershing Square, who along with Valeant (VRX) own 9.7% of Allergan's (AGN) outstanding shares sent a letter on July 16 to Allergan's board which addressed the Allergan's response to Valeantís acquisition proposal. The letter said in part: "In my 21-year history as a governance investor, I cannot think of another example in our portfolio where a board has behaved as poorly as you have in your response to the Valeant merger proposal...You have accused Valeant of fraudulent accounting and of falsifying its reported growth rates and business performance, and you have done so without factual evidence to prove these assertions. If one spreads false and misleading information for the purpose of driving down Valeantís stock price, that is market manipulation, plain and simple. That a board of a $50B market cap company would engage in such behavior as a defensive tactic is extraordinary and incredibly inappropriate. ..We remind you that the current value of Valeantís stock does not reflect the value ultimately received by Allergan shareholders because Valeantís stock currently trades at a substantial discount due to Allerganís scorched earth, negative information campaign against Valeant, the uncertainty of transaction consummation due to Allerganís defensive tactics, and the resulting delays in time to closure...We are now working to obtain the consents to call a special meeting, and upon their receipt, we will ask the board to call the meeting. While under the companyís highly restrictive and cumbersome special meeting mechanics, you have the ability to delay the meeting for up to 120 days, we on behalf of Allerganís other shareholders ask that you do not delay the inevitable any further. What legitimate board of directors attempts to silence or otherwise delay hearing what its own shareholders have to say? Shareholders are looking forward to expressing their views."
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use